China Biopharmaceutical Industry Report, 2006-2007
  • Mar/2007
  • Hard Copy
  • USD $299
  • Pages:25
  • Single User License
    (PDF Unprintable)       
  • USD $299
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $598
  • Hard Copy + Single User License
  • USD $499

In 2006, under the influences of drug depreciation, publishing commercial bribery and the rise in raw material cost, the growth in manufacturing and sales of China pharmaceutical industry slowed down and so did the benefits. Although the sales revenue of the pharmaceutical industry increased by 19.7% year on year, the profit before tax only increased by 6.2%. Since the second quarter of 2006, the growth rate of drugs used in hospitals (first terminal) decreased dramatically to 6.3%, which was the lowest level in recent 10 years; while the retail terminal (second terminal) remained a steady growth, increased by 16.67% over the same period of 2005.

The sales revenue and total profit growth rate of Bio-pharmaceutical industry are 8.2% and 10.9% higher than the average level of pharmaceutical industry respectively, while the sales expenses growth rate is 6.1% lower averagely than the pharmaceutical industry.

Financial Indexes between Bio-pharmaceutical Industry and Pharmaceutical Industry, Jan-Oct, 2006

Since 2005, the growth rate of global pharmaceutical market mainly pulled by North America slowed down to below 10%. Meanwhile, as the multi-national companies began to accelerate the globalization strategy, the Chinese market became the competitive hotspot and the investment featured by the sole proprietorship also increased greatly. Besides, the production & research in patent drugs are gradually localized in Chinese market.

The Chinese government is now taking steps to punish the commercial bribery and to standardize the market rule in the pharmaceutical field, and in addition, the drug price is getting decreased, all of which may temporarily restrict the industrial growth but is helpful to make the pharmaceutical administration much stricter and promote those enterprises superior in innovation of product and technology to enlarge market shares.

Bio-pharmaceuticals mainly engage in prescription drug. The old pharmaceutical products (including bacterin) have become very popular among doctors and patients owing to its higher performance-price ratio, so the sales also kept stable. However, the popularization of the new-born bio-pharmaceuticals in hospitals and disease control centers has to be confronted with the challenges in sales modes and price-making policy from multi-national pharmaceutical giants. So, it is imperative and necessary for sales increase of new prescription drug to catch up with the international academic extension model as soon as possible.

As the investment hotspot of China bio-pharmaceutical industry, the growth of bacterin, especially the bacterin outside plan, is far higher than that of the normal treatable drugs; the R&D of monoclonal antibody drug is quite active because of its strong pertinence and low risks in clinical research.

1. Development Overview of China Bio-pharmaceutical Industry
1.1 Operation Status of China Bio-pharmaceutical Industry in 2006
1.2 Analysis on Key Bio-pharmaceutical Enterprises in China
1.2.1 Beijing Tiantan Biological Products Corporation Limited
1.2.2 Hualan Biological Engineering Inc.
1.2.3 Others

2. Prospect and Opportunities of China Bio-pharmaceutical Industry
2.1 Prospect
2.2 Investment Opportunities
Total Profit Growth Rate of China Bio-pharmaceutical Industry, Jan-Oct 2006
Sales Profit Margin of China Bio-pharmaceutical Industry, Jan-Oct 2006
Monthly Operation Growth Rate of China Bio-pharmaceutical Industry, Jan-Oct 2006
Growth Rate of Financial Indexes of Sub-industries of China Bio-pharmaceutical Industry, Jan-Oct 2006
List of Investment Subjects of China Bio-pharmaceutical Industry, 2007
Leading Products of Biological Institutes under China National Biotec Group
Forecast of Business Integration on Blood Products
Existing Therapeutic Monoclonal Antibody Drugs in China

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号